TDMS Study 89006-06 Pathology Tables
NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 TWO-YEAR CHRONIC Facility: Southern Research Institute Chemical CAS #: 30516-87-1 Lock Date: 06/04/93 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120 CONTROL MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Moribund Sacrifice 5 5 9 7 Natural Death 11 6 7 11 Dosing Accident 2 1 Accidently Killed 1 Survivors Terminal Sacrifice 34 38 31 31 Natural Death 1 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Gallbladder (48) (44) (49) (45) Intestine Large, Rectum (46) (48) (46) (45) Squamous Cell Carcinoma, Metastatic, Vagina 1 (2%) Intestine Small, Jejunum (46) (46) (44) (42) Intestine Small, Ileum (46) (44) (45) (42) Liver (50) (50) (50) (50) Hemangioma 1 (2%) Hemangiosarcoma 2 (4%) Hepatoblastoma 1 (2%) 2 (4%) Hepatocellular Carcinoma 10 (20%) 14 (28%) 10 (20%) 11 (22%) Hepatocellular Carcinoma, Multiple 2 (4%) 3 (6%) 1 (2%) 4 (8%) Hepatocellular Adenoma 14 (28%) 11 (22%) 9 (18%) 19 (38%) Hepatocellular Adenoma, Multiple 6 (12%) 7 (14%) 8 (16%) 9 (18%) Histiocytic Sarcoma 2 (4%) 1 (2%) 1 (2%) 1 (2%) Mesentery (13) (17) (8) (11) Carcinoma, Metastatic, Pancreas 1 (8%) Carcinoma, Metastatic, Uterus 1 (6%) Fibrosarcoma, Metastatic, Skeletal Muscle 1 (8%) Histiocytic Sarcoma 1 (6%) 1 (13%) Sarcoma 2 (15%) Sarcoma, Metastatic, Pancreas 1 (9%) Pancreas (50) (49) (49) (48) Carcinoma 1 (2%) Carcinoma, Metastatic, Uterus 1 (2%) Histiocytic Sarcoma 1 (2%) Sarcoma 1 (2%) Salivary Glands (50) (50) (50) (50) Stomach, Forestomach (49) (49) (49) (49) Histiocytic Sarcoma 1 (2%) Squamous Cell Carcinoma 1 (2%) Page 2 NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120 CONTROL MG/KG ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Squamous Cell Papilloma 3 (6%) 3 (6%) 1 (2%) 1 (2%) Stomach, Glandular (49) (49) (48) (49) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Pancreas 1 (2%) Tongue (1) Squamous Cell Papilloma 1 (100%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (49) (50) (50) (50) Carcinoma, Metastatic, Uterus 1 (2%) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (49) (50) (50) Histiocytic Sarcoma 1 (2%) Capsule, Carcinoma, Metastatic, Uterus 1 (2%) Capsule, Fibrosarcoma, Metastatic, Skeletal Muscle 1 (2%) Islets, Pancreatic (49) (49) (50) (47) Adenoma 2 (4%) 1 (2%) 1 (2%) Pituitary Gland (46) (49) (46) (46) Pars Distalis, Adenoma 2 (4%) 5 (10%) 1 (2%) Thyroid Gland (49) (50) (50) (50) Follicular Cell, Adenoma 3 (6%) 2 (4%) 4 (8%) Follicular Cell, Carcinoma 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Peritoneum (1) Tissue NOS (1) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Clitoral Gland (49) (49) (49) (48) Carcinoma 1 (2%) Ovary (50) (50) (47) (48) Cystadenoma 2 (4%) 2 (4%) 3 (6%) Granulosa Cell Tumor Benign 2 (4%) Hemangioma 1 (2%) Histiocytic Sarcoma 1 (2%) 1 (2%) Teratoma Benign 1 (2%) Page 3 NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120 CONTROL MG/KG ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM - cont Uterus (50) (50) (49) (50) Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) 1 (2%) Leiomyosarcoma 1 (2%) Endometrium, Carcinoma 1 (2%) 1 (2%) Endometrium, Polyp Stromal 1 (2%) 2 (4%) Endometrium, Sarcoma Stromal 1 (2%) Vagina (50) (49) (45) (49) Histiocytic Sarcoma 1 (2%) Squamous Cell Carcinoma 5 (11%) 9 (18%) Squamous Cell Papilloma 2 (4%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (49) (50) (50) Hemangiosarcoma 1 (2%) Histiocytic Sarcoma 1 (2%) Lymph Node (7) (5) (7) (10) Fibrosarcoma, Metastatic, Skin 1 (10%) Iliac, Histiocytic Sarcoma 1 (20%) Inguinal, Carcinoma, Metastatic, Clitoral Gland 1 (10%) Inguinal, Histiocytic Sarcoma 1 (20%) Mediastinal, Histiocytic Sarcoma 1 (14%) Renal, Carcinoma, Metastatic, Clitoral Gland 1 (10%) Renal, Histiocytic Sarcoma 1 (14%) Lymph Node, Mandibular (50) (46) (48) (48) Histiocytic Sarcoma 1 (2%) 1 (2%) Lymph Node, Mesenteric (50) (47) (48) (47) Histiocytic Sarcoma 1 (2%) 1 (2%) 1 (2%) Spleen (49) (48) (49) (50) Hemangiosarcoma 1 (2%) 1 (2%) Sarcoma, Metastatic, Pancreas 1 (2%) Thymus (48) (46) (49) (46) Carcinoma, Metastatic, Uterus 1 (2%) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (50) (49) (50) (50) Trichoepithelioma 1 (2%) Pinna, Squamous Cell Carcinoma 1 (2%) Subcutaneous Tissue, Fibrosarcoma 1 (2%) 2 (4%) 2 (4%) Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ Page 4 NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120 CONTROL MG/KG ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) (50) Carcinoma, Metastatic, Uterus 1 (2%) Skeletal Muscle (50) (50) (50) (50) Carcinoma, Metastatic, Uterus 1 (2%) Fibrosarcoma 1 (2%) Hemangiosarcoma 1 (2%) Sarcoma 1 (2%) Sarcoma, Metastatic, Pancreas 1 (2%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (50) (50) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (49) (50) (50) (50) Alveolar/Bronchiolar Adenoma 3 (6%) 3 (6%) 2 (4%) 7 (14%) Alveolar/Bronchiolar Carcinoma 3 (6%) 5 (10%) 4 (8%) Carcinoma, Metastatic, Clitoral Gland 1 (2%) Carcinoma, Metastatic, Harderian Gland 1 (2%) 1 (2%) Carcinoma, Metastatic, Pancreas 1 (2%) Carcinoma, Metastatic, Uterus 1 (2%) Fibrosarcoma, Metastatic, Skin 2 (4%) Hepatocellular Carcinoma, Metastatic, Liver 3 (6%) 4 (8%) 1 (2%) 2 (4%) Histiocytic Sarcoma 1 (2%) 1 (2%) Leiomyosarcoma, Metastatic, Uterus 1 (2%) Squamous Cell Carcinoma, Metastatic, Vagina 1 (2%) Nose (50) (50) (50) (50) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (5) (2) (2) (2) Adenoma 4 (80%) 2 (100%) 1 (50%) Carcinoma 1 (20%) 1 (50%) 1 (50%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) 1 (2%) Urethra (1) Squamous Cell Carcinoma, Metastatic, Vagina 1 (100%) Urinary Bladder (50) (50) (49) (49) Page 5 NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120 CONTROL MG/KG ____________________________________________________________________________________________________________________________________ URINARY SYSTEM - cont Hemangioma 1 (2%) Hemangiosarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 2 (4%) 1 (2%) 3 (6%) 1 (2%) Lymphoma Malignant 5 (10%) 10 (20%) 7 (14%) 9 (18%) Mesothelioma Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 6 NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE FEMALE VEHICLE 30 MG/KG 60 MG/KG 120 CONTROL MG/KG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 41 42 41 43 Total Primary Neoplasms 70 79 66 92 Total Animals with Benign Neoplasms 30 33 26 31 Total Benign Neoplasms 40 41 31 42 Total Animals with Malignant Neoplasms 26 30 28 35 Total Malignant Neoplasms 30 38 35 50 Total Animals with Metastatic Neoplasms 5 4 3 9 Total Metastatic Neoplasm 8 12 3 15 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 7 NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120 CONTROL MG/KG ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially in Study 50 50 50 50 Early Deaths Natural Death 12 6 9 4 Moribund Sacrifice 6 9 9 4 Accidently Killed 2 Dosing Accident 1 Survivors Terminal Sacrifice 32 35 29 42 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Esophagus (50) (50) (49) (50) Sarcoma, Metastatic, Skin 1 (2%) Gallbladder (41) (42) (46) (44) Intestine Large, Cecum (47) (48) (45) (49) Intestine Small, Duodenum (48) (48) (47) (47) Intestine Small, Jejunum (47) (48) (45) (47) Carcinoma 1 (2%) 2 (4%) 1 (2%) Intestine Small, Ileum (47) (48) (45) (47) Liver (50) (50) (50) (50) Hemangioma 2 (4%) 1 (2%) 1 (2%) Hemangiosarcoma 1 (2%) 2 (4%) 3 (6%) 1 (2%) Hemangiosarcoma, Multiple 5 (10%) 2 (4%) 1 (2%) 2 (4%) Hepatoblastoma 1 (2%) 2 (4%) 5 (10%) 2 (4%) Hepatoblastoma, Multiple 1 (2%) Hepatocellular Carcinoma 17 (34%) 15 (30%) 15 (30%) 15 (30%) Hepatocellular Carcinoma, Multiple 4 (8%) 11 (22%) 7 (14%) 4 (8%) Hepatocellular Adenoma 17 (34%) 19 (38%) 14 (28%) 21 (42%) Hepatocellular Adenoma, Multiple 8 (16%) 4 (8%) 9 (18%) 5 (10%) Hepatocholangiocarcinoma 1 (2%) 1 (2%) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Mesentery (1) (4) (5) (2) Hepatocellular Carcinoma, Metastatic, Liver 1 (20%) Sarcoma 1 (20%) Pancreas (50) (49) (49) (50) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Salivary Glands (50) (49) (49) (50) Hemangioma 1 (2%) Histiocytic Sarcoma 1 (2%) Page 8 NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120 CONTROL MG/KG ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - cont Stomach, Forestomach (50) (48) (49) (50) Stomach, Glandular (50) (48) (49) (50) Sarcoma, Metastatic, Mesentery 1 (2%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (50) (50) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (49) (49) (49) Adenoma 1 (2%) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Capsule, Adenoma 5 (10%) 3 (6%) 1 (2%) 2 (4%) Adrenal Medulla (50) (49) (48) (49) Sarcoma, Metastatic, Mesentery 1 (2%) Islets, Pancreatic (50) (49) (49) (50) Adenoma 1 (2%) 1 (2%) Thyroid Gland (50) (49) (48) (50) Bilateral, Follicular Cell, Adenoma 1 (2%) Follicular Cell, Adenoma 2 (4%) 3 (6%) 2 (4%) 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM Peritoneum (1) Hepatocholangiocarcinoma, Metastatic, Liver 1 (100%) Tissue NOS (1) (1) Hepatocellular Carcinoma, Metastatic, Liver 1 (100%) ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (50) (49) (50) (50) Histiocytic Sarcoma 1 (2%) Preputial Gland (48) (50) (50) (49) Hemangiosarcoma 1 (2%) Prostate (50) (49) (50) (50) Seminal Vesicle (50) (49) (50) (50) Histiocytic Sarcoma 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Testes (50) (49) (50) (50) Page 9 NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120 CONTROL MG/KG ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM - cont Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (50) (49) (50) Hemangiosarcoma 1 (2%) 1 (2%) 1 (2%) Lymph Node (6) (7) (5) (1) Mediastinal, Sarcoma, Metastatic, Skin 1 (17%) Popliteal, Hemangiosarcoma 1 (17%) Renal, Histiocytic Sarcoma 1 (14%) Lymph Node, Mandibular (49) (48) (49) (50) Lymph Node, Mesenteric (48) (49) (49) (49) Hemangiosarcoma 1 (2%) Spleen (50) (49) (48) (50) Hemangioma 1 (2%) Hemangiosarcoma 2 (4%) 1 (2%) Thymus (41) (44) (41) (35) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Skin (50) (50) (50) (50) Subcutaneous Tissue, Chondrosarcoma 1 (2%) Subcutaneous Tissue, Fibrosarcoma 1 (2%) 2 (4%) 1 (2%) Subcutaneous Tissue, Hemangiosarcoma 1 (2%) Subcutaneous Tissue, Histiocytic Sarcoma 1 (2%) Subcutaneous Tissue, Sarcoma 1 (2%) 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Skeletal Muscle (50) (50) (50) (50) Rhabdomyosarcoma 1 (2%) Sarcoma, Metastatic, Mesentery 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (49) (50) Cranial Nerve, Schwannoma Malignant 1 (2%) ____________________________________________________________________________________________________________________________________ Page 10 NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120 CONTROL MG/KG ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (50) (50) (50) Alveolar/Bronchiolar Adenoma 8 (16%) 6 (12%) 9 (18%) 8 (16%) Alveolar/Bronchiolar Adenoma, Multiple 4 (8%) 1 (2%) 2 (4%) Alveolar/Bronchiolar Carcinoma 4 (8%) 2 (4%) 3 (6%) 2 (4%) Alveolar/Bronchiolar Carcinoma, Multiple 2 (4%) Hepatoblastoma, Metastatic, Liver 2 (4%) Hepatocellular Carcinoma, Metastatic, Liver 6 (12%) 2 (4%) 4 (8%) 3 (6%) Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Mediastinum, Hepatocholangiocarcinoma, Metastatic, Liver 1 (2%) Nose (50) (50) (49) (50) Schwannoma Malignant, Metastatic, Brain 1 (2%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Harderian Gland (3) (7) (2) (10) Adenoma 3 (100%) 2 (29%) 2 (100%) 10 (100%) Carcinoma 3 (43%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (48) (49) (50) Hepatocellular Carcinoma, Metastatic, Liver 1 (2%) Sarcoma, Metastatic, Skin 1 (2%) Renal Tubule, Adenoma 3 (6%) Renal Tubule, Carcinoma 1 (2%) Urinary Bladder (50) (50) (50) (50) Histiocytic Sarcoma 1 (2%) ____________________________________________________________________________________________________________________________________ SYSTEMIC LESIONS Multiple Organs *(50) *(50) *(50) *(50) Histiocytic Sarcoma 2 (4%) Lymphoma Malignant 1 (2%) 6 (12%) 7 (14%) 5 (10%) ____________________________________________________________________________________________________________________________________ * Number of animals with any tissue examined microscopically Page 11 NTP Experiment-Test: 89006-06 INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a) Report: PEIRPT05 Study Type: CHRONIC AZT Date: 05/31/96 Route: GAVAGE Time: 12:48:52 ____________________________________________________________________________________________________________________________________ B6C3F1 MICE MALE VEHICLE 30 MG/KG 60 MG/KG 120 CONTROL MG/KG ____________________________________________________________________________________________________________________________________ TUMOR SUMMARY Total Animals with Primary Neoplasms (b) 43 49 45 50 Total Primary Neoplasms 90 96 91 88 Total Animals with Benign Neoplasms 33 31 29 42 Total Benign Neoplasms 49 42 42 51 Total Animals with Malignant Neoplasms 28 40 39 29 Total Malignant Neoplasms 41 54 49 37 Total Animals with Metastatic Neoplasms 6 3 9 3 Total Metastatic Neoplasm 13 3 22 3 Total Animals with Malignant Neoplasms Uncertain Primary Site Total Animals with Neoplasms Uncertain- Benign or Malignant Total Uncertain Neoplasms ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion b Primary tumors: all tumors except metastatic tumors Page 12 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------